scholarly journals A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma

2016 ◽  
Vol 7 (2-3) ◽  
pp. 40-44 ◽  
Author(s):  
Nobumichi Takeuchi ◽  
Shun Miyazawa ◽  
Zentaro Ohno ◽  
Sonomi Yoshida ◽  
Tetsu Tsukamoto ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Spontaneous Tumor Lysis Syndrome

Spontaneous clinical tumor lysis syndrome in solid renal tumor: first case report in non-metastatic renal carcinoma

2020 ◽  
Vol 4 (3) ◽  
pp. 124-127
Author(s):  
Bruno Nogueira Cesar ◽  
Nilo Eduardo Delboni Nunes ◽  
Maria Amelia Aguiar Hazin ◽  
Renato Demarchi Foresto ◽  
Gianna Mastroianni Kirsztajn ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
First Case ◽  
Spontaneous Tumor Lysis Syndrome ◽  
Hematological Tumors

Spontaneous tumor lysis syndrome is a rare emergency in onco-nephrology that results from extensive cancer cell lysis independent of antitumoral therapy. It is common among hematological tumors and can be rarely seen with solid tumors. In medical literature, there is only one case report with spontaneous tumor lysis syndrome in renal cell carcinoma and it was associated with metastases. To the best of our knowledge, this is the first report of spontaneous tumor lysis syndrome in non-metastatic renal cell carcinoma.

scholarly journals Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist

2020 ◽  
Vol 8 ◽  
pp. 232470962094470 ◽  
Author(s):  
Vishal Patel ◽  
Robert Case
Keyword(s):  
Uric Acid ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Tumor Lysis Syndrome ◽  
General Internist ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Mantle Cell ◽  
Spontaneous Tumor Lysis Syndrome

Spontaneous tumor lysis syndrome (SPTLS) is a rare phenomenon that can manifest in rapidly proliferating hematological malignancies and solid tumors prior to initiating cytotoxic therapy. We encountered a patient who originally presented with diffuse lymphadenopathy, abdominal distention, and dyspnea, who had laboratory abnormalities suggestive of SPTLS. His peripheral flow cytometry and lymph node biopsy revealed blastoid-variant mantle cell lymphoma. Prior to initiating chemotherapy, acute kidney injury (AKI) and uric acid had improved with intravenous fluids and the initiation of allopurinol. However, after beginning chemotherapy, the patient developed a second AKI concerning for tumor lysis syndrome (TLS). He went on to have renal recovery and did not require renal replacement therapy. With the exception of case reports, there is limited evidence to guide general medicine clinicians who encounter cases of SPTLS. Expert-based guidelines are available to guide use of rasburicase, an uricase enzyme, before initiation of chemotherapy for certain malignancies when risk for TLS is considered high. Despite these guidelines, the role of rasburicase in preventing AKI remains controversial after inconclusive results in a meta-analysis. The causative relationship between uric acid and AKI in TLS is based on a mechanism of tubular obstruction. There are also mechanisms by which uric acid may cause AKI without tubular obstruction related to acute hyperuricemic nephropathy. Further characterization of the role of uric acid in causing AKI in patients without tubular obstruction may identify new mechanisms of injury and offer insight into new treatment strategies.

scholarly journals Spontaneous Tumor Lysis Syndrome

2020 ◽  
Vol 13 (3) ◽  
pp. 1116-1124
Author(s):  
Wiebke Wesemüller ◽  
Christian Taverna
Keyword(s):  
Tumor Therapy ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Oncological Emergency ◽  
Life Saving ◽  
Cytotoxic Treatment ◽  
Tumor Load ◽  
Spontaneous Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is a hemato-oncological emergency characterized by metabolic and electrolyte imbalances which are associated with disintegrating tumor cells. The syndrome is frequently observed when starting cytotoxic treatment of hematological malignancies, while the incidence of spontaneous tumor lysis prior to the start of tumor therapy is rare. Here, we present a case of spontaneous TLS in a male patient who was referred with unspecific symptoms and suspected metastatic malignancy. He developed acute renal failure before the diagnosis of a high-grade B-cell lymphoma (double hit lymphoma) and start of therapy. Although the course of TLS would have required intensive care, the patient rejected such treatment for personal reasons and died soon after the discontinuation of therapy. The case emphasizes the life-saving relevance of early detection and appropriate treatment of TLS. It also demonstrates the importance of actively screening for TLS, primarily in patients with malignant diseases and high tumor load, even if they are not receiving cytotoxic therapy.

scholarly journals Spontaneous Tumor Lysis Syndrome Secondary to Small-Cell Neuroendocrine Carcinoma of Unknown Origin: A Rare Case Report and Literature Review

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Phyo Thazin Myint ◽  
Hifza Waheed Butt ◽  
Taha Alrifai ◽  
Carlos Marin
Keyword(s):  
Tumor Lysis Syndrome ◽  
Unknown Origin ◽  
Small Cell ◽  
Tumor Patients ◽  
Large Tumor ◽  
Comfort Care ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Rare Case Report ◽  
Spontaneous Tumor Lysis Syndrome

Spontaneous tumor lysis syndrome (STLS), in the absence of prior chemo or radiation therapy, is rare with solid tumors. Here, we present a case of STLS secondary to a small-cell neuroendocrine tumor of unknown origin in a 66-year-old female patient who presented with abdominal discomfort. Computed tomography (CT) abdomen showed a large tumor mass with peritoneal metastasis, and she developed renal failure from STLS, resulting in the need for hemodialysis. Due to the progressive deterioration and the comorbidities, she opted for comfort care. Timely recognition and intervention of STLS is critical. Further studies evaluating STLS in solid tumor patients are recommended.

Sign in / Sign up

Export Citation Format

Share Document